Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2012

View Archived Issues

Genomic biomarker panel predicts COPD exacerbations

AstraZeneca and Dainippon Sumitomo Pharma present new TLR7 agonists

British group divulges new bifunctional agents

Lundbeck discloses new PDE10A inhibitors

Katholieke Universiteit Leuven patents novel agents for HIV

New phase II INNO-206 trial launched

Incyte synthesizes novel JAK-1 inhibitors

New biomarker panel discovered for use in spinal muscular atrophy research

LY-2881835 shows antidiabetic activity in vivo

Stratatech skin substitute receives FDA orphan drug status

New anticancer agents prepared by Indian company

Johnson & Johnson completes acquisition

Georgetown University presents novel ezrin inhibitors

MD Anderson Cancer Center joins phase I LOR-253 study

International team of researchers develops novel cancer treatments

GL-ONC1 combination study begins in advanced head and neck cancer

DreaMS study reveals benefit of ONO-4641

Research underlying BioLineRx project wins award

Innovimmune Biotherapeutics obtains NIH grant

Treatment begins in new Actimab-A study

Teva discloses topline data from phase III GALA trial

BrainStorm Cell Therapeutics receives grant for autologous adult stem cell product development

Theraclone product enters phase I testing for CMV infection

Data and safety monitoring board recommends continuation of vosaroxin trial

Phase II oregovomab study in ovarian cancer opens in U.S.

PharmAthene advances development of anthrax vaccine

Phase II results reported for oral interferon alpha in hepatitis C

FDA approves MenHibrix

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...